Dreamit has teamed with Accenture, one of the world’s leading professional services companies, to connect Accenture’s strategy and innovation leadership to the startup founders at Dreamit working on transformational products in health tech and urban tech.
This semester, FastForward U (FFU) will begin offering entrepreneurial advising to students looking to start a company or business venture. FFU is an initiative from Johns Hopkins Technology Ventures (JHTV), an office that facilitates licensing and patents for Hopkins researchers and supports technology startups.
The Association of University Research Parks (AURP) today announced the recipients of the Awards of Excellence recognized during its 2017 International Conference hosted by Cummings Research Park in Huntsville, AL. Additionally, AURP announced the results of the election for its 2018 Board of Directors.
Monday, December 11, 2017
Apella, Alexandria Center for Life Science 6:00 – 7:30 PM
Brick by brick, and startup by startup, the New York biotech scene is slowly being built up. More startup incubators are either up, or in development, than ever before. Several pieces necessary to a functional life sciences ecosystem are now in place, and many other milestones will simply take time to develop and succeed. Yet industry and government leaders, investors, and entrepreneurs can’t get complacent—there is much more that New York can do, right now, to gain ground on other hubs and further establish the region as a top center for life science. If the right progress is made, 2018 could be a signature year for the city—or, if progress proves elusive, the momentum could slip away.
The National Institutes of Health and 11 leading biopharmaceutical companies today launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers — standardized biological markers of disease and treatment response — to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership will be managed by the Foundation for the National Institutes of Health (FNIH), with the Food and Drug Administration serving in an advisory role.
When someone’s body parts are donated, it’s a life-or-death race against the clock as hearts, lungs, livers and hands rapidly deteriorate outside the body.
The partnership will see GamaMabs use MedImmune’s proprietary pyrrolobenzodiazepine (PBD) toxin and linker technology in the research and production of the ADC for targeted cancer therapy. GamaMabs will have exclusive rights to use the proprietary PBD technology in this work and MedImmune will receive an upfront payment, development and commercial milestone payments as well as royalties on net sales.
Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company is proud to announce a travel fund for patients enrolled in a Phase II clinical study that employs their investigational LAMP-Vax™ technology to treat glioblastoma multiforme (GBM).
We invite you to participate in the East County Regional Job Fair to be held on Thursday, November 2, 2017 from 3:00 –7:00pm at the East County Community Recreation Center, 3310 Gateshead Manor Way, Silver Spring, MD 20904. We ask that you complete this form by October 25th. We encourage all employers to set-up between 1:00 – 2:30 since the event will start at 3pm prompt!
Lupin said today it has acquired Symbiomix Therapeutics for $150 million cash, in a deal designed to expand the buyer’s branded women’s health specialty drug business.
In acquiring Symbiomix through its U.S. subsidiary, Lupin has exercised an option it retained earlier this year to buy the privately held developer of treatments for gynecologic infections.
